New treatment plans based on CTCL genetic type
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cutaneous T-cell lymphoma (CTCL) that didn't get better with skin treatments (like creams, light therapy, or nitrogen mustard).
- You are between 18 and 75 years old.
- Your doctor expects you to live at least 3 more months.
- You haven't had any other cancer treatment (besides skin treatments) in the past month.
- You don't have another cancer that you're still treating.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
Hear when a new Cutaneous T-Cell Lymphoma/Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.